COVID-19

A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.

Also Known As:

COVID19; 2019 nCoV Disease; 2019 nCoV Infection; 2019-nCoV Diseases; 2019-nCoV Infections; COVID 19; COVID 19 Pandemic; COVID 19 Virus Disease; COVID 19 Virus Infection; COVID-19 Virus Diseases; COVID-19 Virus Infections; Coronavirus Disease 19; Disease 2019, Coronavirus; Disease, 2019-nCoV; Disease, COVID-19 Virus; Infection, 2019-nCoV; Infection, COVID-19 Virus; Infection, SARS-CoV-2; Pandemic, COVID-19; SARS CoV 2 Infection; SARS-CoV-2 Infections; Virus Disease, COVID-19; Virus Infection, COVID-19; 2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infection; COVID-19 Pandemic; COVID-19 Pandemics; COVID-19 Virus Disease; COVID-19 Virus Infection; Coronavirus Disease 2019; Coronavirus Disease-19; SARS Coronavirus 2 Infection; SARS-CoV-2 Infection; Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Infections: 526564
- Virus Diseases: 41777
  - Viral Pneumonia: 577
    - COVID-19: 109434
  - RNA Virus Infections: 303
    - Nidovirales Infections
      - Coronaviridae Infections: 1
        Coronavirus Infections: 1279
        COVID-19: 109434
- Respiratory Tract Infections: 14082
  - Pneumonia: 52735
    - Viral Pneumonia: 577
      - COVID-19: 109434
Respiratory Tract Diseases: 6015
- Lung Diseases: 22246
  - Pneumonia: 52735
    - Viral Pneumonia: 577
      - COVID-19: 109434
- Respiratory Tract Infections: 14082
  - Pneumonia: 52735
    - Viral Pneumonia: 577
      - COVID-19: 109434

1.	COVID-19 10/01/2022 - "The present phase 1 study aimed to determine the safety of Codivir, a newly developed anti-viral agent, and to preliminarily assess its anti-viral activity in patients infected by COVID-19. "

Codivir

Bio-Agent Context: Research Results

Related Diseases